Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib plus Sintilimab in Advanced NET G3, NEC, and Pancreatic Carcinoma
NCT05627427Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jul 2022
- Primary completion
- Apr 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib in Neuroendocrine Neoplasm (NEN), neuroendocrine carcinoma (NEC) and pancreatic carcinoma, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Progression-free Survival at 2 years. Status: unknown.
02
Drugs
surufatinib
03
Conditions
Neuroendocrine Neoplasm (NEN)neuroendocrine carcinoma (NEC)pancreatic carcinoma
Beyond the preview
Go deeper on NCT05627427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05627427.